ArticleMolecular diagnosis & therapy2023

Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.

Tobin J Cammett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.